These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12821458)

  • 21. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.
    Hsu A; Granneman GR; Cao G; Carothers L; Japour A; El-Shourbagy T; Dennis S; Berg J; Erdman K; Leonard JM; Sun E
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2784-91. PubMed ID: 9797204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Hoetelmans RM; Mulder JW; Schreij G; Hsu A; Lange JM; Beijnen JH; Meenhorst PL
    AIDS; 1999 Oct; 13(14):F95-9. PubMed ID: 10513637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.
    Young B; Fischl MA; Wilson HM; Finn TS; Jensen EH; DiNubile MJ; Zeldin RK
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):478-82. PubMed ID: 12473835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.
    Martin C; Sönnerborg A; Svensson JO; Ståhle L
    AIDS; 1999 Jul; 13(10):1227-32. PubMed ID: 10416527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
    Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J; Phanupak P; Reiss P
    J Antimicrob Chemother; 2003 May; 51(5):1231-8. PubMed ID: 12668574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.
    Tappouni HL; Rublein JC; Donovan BJ; Hollowell SB; Tien HC; Min SS; Theodore D; Rezk NL; Smith PC; Tallman MN; Raasch RH; Kashuba AD
    Am J Health Syst Pharm; 2008 Mar; 65(5):422-8. PubMed ID: 18281734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.
    Shulman N; Zolopa A; Havlir D; Hsu A; Renz C; Boller S; Jiang P; Rode R; Gallant J; Race E; Kempf DJ; Sun E
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3907-16. PubMed ID: 12435695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
    Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1170-6. PubMed ID: 22250979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting.
    Boffito M; Bonora S; Raiteri R; Reynolds HE; Hoggard PG; Sinicco A; Back DJ; Di Perri G
    Ther Drug Monit; 2002 Aug; 24(4):574-6. PubMed ID: 12142647
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
    Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
    Bertrand J; Treluyer JM; Panhard X; Tran A; Auleley S; Rey E; Salmon-Céron D; Duval X; Mentré F;
    Eur J Clin Pharmacol; 2009 Jul; 65(7):667-78. PubMed ID: 19440701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
    Glesby MJ; Aberg JA; Kendall MA; Fichtenbaum CJ; Hafner R; Hall S; Grosskopf N; Zolopa AR; Gerber JG;
    Clin Pharmacol Ther; 2005 Aug; 78(2):143-53. PubMed ID: 16084849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.
    Burger DM; Hugen PW; Aarnoutse RE; Dieleman JP; Prins JM; van der Poll T; ten Veen JH; Mulder JW; Meenhorst PL; Blok WL; van der Meer JT; Reiss P; Lange JM
    J Acquir Immune Defic Syndr; 2001 Mar; 26(3):218-24. PubMed ID: 11242194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
    Cressey TR; Leenasirimakul P; Jourdain G; Tod M; Sukrakanchana PO; Kunkeaw S; Puttimit C; Lallemant M
    J Antimicrob Chemother; 2005 Jun; 55(6):1041-4. PubMed ID: 15883177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
    Pelton SI; Stanley K; Yogev R; Fletcher CV; McIntosh K; Wiznia A; Nachman S;
    Clin Infect Dis; 2005 Apr; 40(8):1181-7. PubMed ID: 15791520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data.
    Solas C; Petit N; Orticoni M; Durand A; Gastaut JA; Lacarelle B
    Pathol Biol (Paris); 2002 Nov; 50(9):565-7. PubMed ID: 12490421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
    Ghosn J; Lamotte C; Ait-Mohand H; Wirden M; Agher R; Schneider L; Bricaire F; Duvivier C; Calvez V; Peytavin G; Katlama C
    AIDS; 2003 Jan; 17(2):209-14. PubMed ID: 12545081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.